Literature DB >> 17374735

Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.

Nassr Nassr1, Gezim Lahu, Andreas Hünnemeyer, Oliver von Richter, Dietrich Knoerzer, Felix Reutter, Karl Zech, Robert Hermann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17374735     DOI： 10.1177/0091270006297920

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  5 in total

Review 1.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 2.  Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Authors:  Klaus F Rabe
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

3.  Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Authors:  Gezim Lahu; Andreas Hünnemeyer; Edgar Diletti; Martin Elmlinger; Peter Ruth; Karl Zech; Nigel McCracken; Axel Facius
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

Review 4.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Authors:  Mark A Giembycz; Stephen K Field
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

5.  Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.

Authors:  Robert Hermann; Nassr Nassr; Gezim Lahu; Eva Péterfai; Dietrich Knoerzer; Rolf Herzog; Karl Zech; Christian de Mey
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.